Friday, April 10, 2026Â
| Session | Time | Room | Title | Organizers | ||
|---|---|---|---|---|---|---|
| OpportuNet: Networking Fair | 7:30 – 1:15pm | Gallery #1017 | Open during duration of symposium | Taylor Krajewski (Duke) | ||
| Opening Remarks | 8:30 – 9:00am | Auditorium EBC250 | Welcome Poster Award Presentations DISS Steering Committee Remarks | Herb Pang (Genentech) Roland Matsouaka / Lisa Wruck (Duke) TBD (Affiliation) | ||
| Keynote II | 9:00 – 10:00am | Auditorium EBC250 | Dr. Udo Sglavo, Vice President, Applied AI and Modeling R&D, SAS Institute Inc. | Fang Chen (SAS Institute Inc.) | ||
| Break | 10:00 – 10:15am | |||||
| S4A | 10:15 – 11:45am | Not yet assigned | AI-Driven Analytics: How Modern-Day Statistical Software Charts the Future of Innovation | Fang Chen (SAS) | ||
| S4B | 10:15 – 11:45am | Not yet assigned | Conformal Inference for Uncertainty-Aware Machine Learning in Biomedical Research | Ke Zhu (Duke) | ||
| S4C | 10:15 – 11:45am | Not yet assigned | Expediate Dose Optimization Using Backfill and Randomization | Ying Yuan (University of Texas) | ||
| S4D | 10:15 – 11:45am | Not yet assigned | From Data to Decisions: Bayesian Approaches to Drug Exposure and Dosing | Kevin Gan (ViiV) | ||
| Lunch | 11:45 – 1:15pm | SAS Cafe (Lower Level) Seating Area TBD | ||||
| OpportuNet: Networking Fair | 12:30 – 1:15pm | Gallery #1017 | Designated time for networking with sponsor representatives. OpportuNet ends at 1:15pm | Taylor Krajewski (Duke) | ||
| S5A | 1:15 – 3:00pm | Not yet assigned | AI/Machine Learning Applications and Methods in Clinical Trials | Zoe Hua (Servier) | ||
| S5B | 1:15 – 3:00pm | Not yet assigned | Empower Pharmaceutical Developments with Innovative Adaptive Clinical Trials | Kaiyuan Hua (BeOne Medicines) | ||
| S5C | 1:15 – 3:00pm | Not yet assigned | Advancing Quantitative Benefit–Risk Assessment in Drug Development: Methodologies, Applications, and Regulatory Perspectives | Zhangyang Teng (Astellas) | ||
| S5D | 1:15 – 3:00pm | Not yet assigned | Go/No-Go Decision Making of Transitioning to Phase 3 Study in Clinical Development | Kentaro Takeda (Astellas) |
